Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zalcitabine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Zalcitabine | DRUG | - |
Inclusion Criteria Concurrent Medication: Recommended: * Prophylactic aerosolized pentamidine. * Allowed for maintenance after recovering from infection for which initially prescribed: * Pyrimethamine. * Sulfadiazine. * Amphotericin. * Fluconazole. * Ketoconazole (= or \< 400 mg/day). * Acyclovir...
Top 20 of 28 competitors
Zalcitabine is a small molecule drug being developed for the treatment of HIV infections. It is currently in Phase 2 clinical development and is being studied in patients with AIDS or advanced ARC who have shown intolerance to zidovudine (AZT).
Zalcitabine is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and tolerability in patients with HIV infections.
Zalcitabine is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and there are no active trials currently ongoing.
Zalcitabine has one completed clinical trial, identified as NCT00002265. This was an open-label, multicenter study conducted in the United States to evaluate the safety and tolerability of dideoxycytidine (ddC) in patients with AIDS or advanced ARC who previously demonstrated intolerance to zidovudine (AZT).
Yes, Zalcitabine is also known as dideoxycytidine (ddC). In clinical trials, it is referred to by this alternative name, and the completed study NCT00002265 evaluates the safety and tolerability of ddC in patients with HIV infections.